KOSDAQElectrical Equipment303360

Protia

₩2,705▲ 1.50%2026-11-18 close
Market Cap
₩52.3B
Turnover
₩88,279,480
Volume
30K
Shares out.
19.3M
PER
9.0×
PBR
1.2×
EPS
₩361
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Margin turnaround confirmed; quarterly swings are the test

Protia lifted its operating margin to 24.6% in 2025, but Q3 2026 operating profit and profit attributable to controlling shareholders both fell from the prior quarter, keeping quarterly volatility as the key test.

  1. 1

    Revenue has risen for three straight years since 2023, reaching KRW 15.1 billion in 2025, when operating profit was KRW 3.72 billion.

  2. 2

    Operating margin rose from 2.0% in 2023 to 24.6% in 2025, and the company said cumulative revenue and operating profit through Q3 2026 were record highs.

  3. 3

    Allergy and autoimmune diagnostic products received EU CE-IVDR certification on November 6, 2026, opening the route to overseas sales.

  4. 4

    Q3 2026 operating profit fell 30.5% from the prior quarter to KRW 1.14 billion, and profit attributable to controlling shareholders dropped 65.7% year on year to KRW 441 million.

  5. 5

    A 50% bonus issue was decided on September 29, 2026, with the new shares listed on November 5, lifting total common shares to 19,319,572.

02

Business structure

Protia (303360) is a company specializing in in vitro diagnostic medical devices. Its core business is allergy diagnostics, and its flagship product, Protia Allergy-Q 192D, uses molecular diagnostic technology built on recombinant proteins to test for many allergens at once.

The lineup has widened to include allergy diagnostics for humans and animals, autoimmune disease diagnostics, food intolerance tests, rapid antibiotic susceptibility testing, and immune monitoring.

In Korea, its main customers are large health screening centers and contract laboratories, and a first-half 2026 report said it had supplied diagnostic equipment to nine of the top ten such centers and contractors. The same report said domestic allergy diagnostic sales grew more than 80% year on year.

Exports began in India, Russia, Southeast Asia and the Middle East and have since expanded into North America, and a 2025 report expected export share to exceed half of annual revenue for the first time.

On November 6, 2026, the company's allergy and autoimmune diagnostic products obtained EU CE-IVDR certification, which provides a base for overseas sales. Competition runs along two fronts: placing equipment first at large domestic institutions and expanding the number of export countries. The company has set a target of KRW 100 billion in annual revenue by 2030.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩4B₩1.2B29.1%
2025Q4₩4.5B₩1.1B24.0%
2026Q1₩3.8B₩800M19.9%
2026Q2₩5.3B₩1.6B30.6%
2026Q3₩4.7B₩1.1B24.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩7.6B₩1.1B₩1.3B13.8%7.8%8.9%
2023₩8.2B₩200M₩500M2.0%2.0%6.8%
2024₩10.5B₩1.5B₩2.4B14.3%9.3%6.3%
2025₩15.1B₩3.7B₩4.5B24.6%14.6%7.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-11

04

Earnings analysis

Annual results show revenue and profit growing together.

Revenue rose from KRW 7.64 billion in 2022 to KRW 8.23 billion in 2023 (up 7.6% year on year), KRW 10.5 billion in 2024 (up 27.8%), and KRW 15.1 billion in 2025 (up 43.8%), marking three straight years of growth from 2023 through 2025, with 2025 the largest year in the 2022 to 2025 span.

Operating profit fell to a low of KRW 164 million in 2023 (down 84.5% year on year), then rose to KRW 1.5 billion in 2024 (up 815.3%) and KRW 3.72 billion in 2025 (up 147.8%), growing for two consecutive years from 2024 through 2025.

Operating margin moved from 13.8% in 2022 to 2.0% in 2023, then 14.3% in 2024 and 24.6% in 2025.

Profit attributable to controlling shareholders fell from KRW 1.25 billion in 2022 to KRW 463 million in 2023 (down 63.0%), then rose to KRW 2.44 billion in 2024 and KRW 4.47 billion in 2025, growing for two consecutive years.

Net profit including non-controlling interests was reported at the same amounts as profit attributable to controlling shareholders in every year from 2022 to 2025. The company has said that high manufacturing costs at the launch of new products ease once production moves to mass-production levels (Edaily report).

The debt ratio was 8.9% in 2022 and 7.6% in 2025. At year-end 2025, total equity was KRW 30.7 billion, all attributable to controlling shareholders, and total liabilities were KRW 2.33 billion. Operating cash flow was KRW 1.22 billion in 2022, KRW 381 million in 2023, KRW 1.44 billion in 2024 and KRW 3 billion in 2025.

The quarterly pattern was more volatile.

Revenue went from KRW 4.03 billion in Q3 2025 to KRW 4.55 billion in Q4 2025 (up 12.7% quarter on quarter), then KRW 3.82 billion in Q1 2026 (down 15.9%), KRW 5.35 billion in Q2 2026 (up 39.9%) and KRW 4.68 billion in Q3 2026 (down 12.6% quarter on quarter, up 15.9% year on year).

Operating profit peaked at KRW 1.64 billion in Q2 2026 (up 115.4% quarter on quarter) before falling to KRW 1.14 billion in Q3 2026 (down 30.5% quarter on quarter, down 3.3% year on year).

Profit attributable to controlling shareholders dropped to KRW 441 million in Q3 2026 (down 71.5% quarter on quarter, down 65.7% year on year), a sharp gap from the KRW 1.14 billion operating profit in the same quarter.

Profit attributable to controlling shareholders for the latest four quarters, Q4 2025 through Q3 2026, totals KRW 4.65 billion.

In its November 11, 2026 disclosure, the company said cumulative revenue and operating profit through Q3 were record highs, driven by domestic sales of its allergy products, where Allergy-Q line sales rose more than 50% year on year.

05

Industry analysis

The in vitro diagnostics market that Protia serves has been projected by industry sources to reach about KRW 73 trillion globally by 2030.

The market classification lists the company under electrical equipment, but its revenue structure rests on diagnostic products, so comparisons with the electrical equipment sector average may not fit the business.

On seasonality, one report noted that the industry's second-half revenue tends to exceed first-half revenue. In Korea, the competitive approach centers on placing equipment early at large screening centers and contract laboratories, and whether revenue continues after placement must be confirmed quarter by quarter.

Overseas, Kiwoom Securities said in a June 2026 report that growth continues in existing core markets such as Russia and Malaysia while entry into new markets including Canada, Australia and New Zealand is widening.

The EU IVDR is described as the essential gateway for global market entry, so the November 2026 certification meets the entry condition for European sales. Certification does not by itself translate into revenue, however, and local distribution and regulatory execution will determine actual sales.

On the bullish side, product competitiveness and an export base are building together. On the bearish side, export countries and product mix remain concentrated. Both factors will be tested in future quarterly results.

06

Outlook

The company's direction can be summarized as expanding overseas sales and raising the share of higher-margin exports. After CE-IVDR certification, the company said it would expand overseas sales and raise the share of exports, which it considers more profitable, to pursue revenue growth and margin improvement together.

The certification covers both allergy and autoimmune diagnostic products, so overseas revenue from these two product groups is the next point to confirm. The company has set a target of KRW 100 billion in annual revenue by 2030, which assumes very large growth from the KRW 15.1 billion recorded in 2025.

In a June 2026 report, Kiwoom Securities projected 2026 annual revenue of KRW 21.69 billion, operating profit of KRW 6.02 billion and an operating margin of 28%. That estimate was made before the Q3 2026 results, so the Q4 trajectory will be a key variable against the cumulative figures.

On shareholder returns, a 50% bonus issue was decided on September 29, 2026, with capital reserves transferred into share capital. The company said it would gradually expand shareholder returns, including dividends, reflecting profit levels and financial capacity.

Because the bonus issue increased the number of shares, per-share metrics now reflect a different share base, so comparisons with earlier figures require adjusting for share count. The company also plans to keep investing in global R&D.

The next checkpoints are the annual operating margin and dividend plan in the 2026 annual report, and the overseas revenue share in the Q1 2027 quarterly report.

07

Valuation

PER
9.0×
PBR
1.2×
ROE
14.8%
EPS
₩361
BPS
₩2,614
Dividend per share
₩0

Market capitalization is well above the KRW 4.65 billion total of profit attributable to controlling shareholders over the latest four quarters. Measured against total equity of KRW 30.7 billion, the market value sits at a premium to net assets.

On an earnings basis, the multiple has become more sensitive to quarterly swings after profit attributable to controlling shareholders fell 65.7% year on year in Q3 2026.

Comparing the multiple with the electrical equipment sector average is of limited use because the business profile differs, and it is more meaningful against in vitro diagnostics companies.

The company moved from a loss-making structure in 2019 to profitability in 2025, and its equity base expanded substantially over the same period. Because the bonus issue increased the share count, per-share figures should be checked for adjustment before comparing them with earlier periods.

On dividends, the company said it would gradually widen shareholder returns, including dividends, reflecting profit levels and financial capacity.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-11

08

Bull factors

Structural margin improvement

Operating profit grew for two consecutive years from 2024 through 2025, supporting the case for a change in earnings structure. In a June 2026 report, Kiwoom Securities said the full product lineup had settled into mass production and entered a phase of operating leverage.

EU certification opens overseas sales

On November 6, 2026, allergy and autoimmune diagnostic products obtained EU CE-IVDR certification, providing a base for overseas sales. The company said it would raise the share of exports, which it views as more profitable, to pursue revenue growth and margin improvement together.

Export markets have broadened from existing markets such as Russia and Malaysia to Canada, Australia and New Zealand.

Low-leverage balance sheet and shareholder return intent

At year-end 2025, total equity was KRW 30.7 billion and total liabilities were KRW 2.33 billion, leaving a debt ratio of 7.6%. The 50% bonus issue disclosed on September 29, 2026 was aimed at raising shareholder value and expanding share capital.

The company said it would gradually widen shareholder returns, including dividends, reflecting profit levels and financial capacity. Operating cash flow of KRW 3 billion in 2025 was the largest of the 2022 to 2025 period.

09

Bear factors

Large quarterly profit swings

Operating profit fell 30.3% quarter on quarter in Q1 2026 and dropped another 30.5% in Q3 2026. Profit attributable to controlling shareholders in Q3 2026 was KRW 441 million, down 65.7% year on year, a steeper decline than operating profit. If large quarterly swings keep recurring, annual earnings become harder to predict.

Export concentration and execution after certification

Exports were concentrated in India, Russia, Southeast Asia and the Middle East and can be affected by local policy and demand shifts. EU certification was completed in November 2026, but overseas sales after certification are not yet visible in quarterly disclosures. Because a higher export share is the premise for margin improvement, execution speed is central.

Scale gap and product concentration

Revenue of KRW 15.1 billion in 2025 is far from the KRW 100 billion target for 2030. Revenue is concentrated in the allergy diagnostics product family, which leaves the company exposed to competitive shifts in that single group.

The bonus issue raised total common shares to 19,319,572, so changes in tradable supply could add to share price volatility.

10

Risk factors

Earnings volatility

Quarterly operating profit and profit attributable to controlling shareholders have swung sharply in 2026, and this pattern was most visible this year.

In Q3 the gap between operating profit and profit attributable to controlling shareholders widened, and the non-operating and tax factors behind that gap are items to confirm in upcoming quarterly reports. If the pattern persists, confidence in annual earnings trajectories could weaken.

Certification and overseas execution

EU certification is a prerequisite for European sales, but starting sales and getting revenue recognized are separate steps. Regulatory requirements and distribution structures can differ across export countries, which may delay revenue recognition. If the overseas expansion plan slips, the timing of margin improvement could also be pushed back.

Product transitions and R&D costs

The company has explained that high manufacturing costs in the early stage of a new product launch can weigh on profit. It has said it will keep investing in global R&D, so research spending may remain a continuing burden.

The larger share count after the bonus issue also leaves tradable supply as a source of share price fluctuation.

11

What to watch next

  1. By March 31, 2027

    Annual report for fiscal 2026. Key points are whether the annual operating margin holds near the 24.6% recorded in 2025, how much Q4 operating profit offsets the Q3 decline, and whether a dividend plan is set out.

  2. By May 15, 2027

    Q1 2027 quarterly report. Points to confirm are whether overseas sales of EU-certified products appear in results, whether the export share rises, and whether Q1 operating profit exceeds the KRW 760 million recorded in Q1 2026.

  3. Before March 31, 2027 (schedule not confirmed)

    The effect of the larger share count after the bonus issue on tradable supply and per-share metrics. Whether the stated gradual expansion of shareholder returns leads to a concrete dividend decision.

12

Overall view

As a diagnostics company, Protia raised its operating margin from 2.0% in 2023 to 24.6% in 2025, and the company said cumulative results through Q3 2026 were record highs. Revenue has grown for three straight years since 2023, and a debt ratio of 7.6% indicates a light financial burden.

Completion of EU CE-IVDR certification has laid the groundwork for overseas expansion. On the other side, quarterly results in 2026 have moved up and down, and profit attributable to controlling shareholders fell 65.7% year on year in Q3.

Because overseas sales are not yet visible in quarterly disclosures, the durability of the margin shift needs to be tested against additional quarterly data.

Market capitalization is well above the latest four quarters of profit attributable to controlling shareholders, so the pace of earnings recovery is the central variable for valuation.

The next checkpoints are the annual operating margin in the 2026 annual report and the reflection of overseas revenue in the Q1 2027 report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. comp.fnguide.com
  2. sedaily.com
  3. tipranks.com
  4. edaily.co.kr
  5. edaily.co.kr
  6. edaily.co.kr
  7. pharm.edaily.co.kr
  8. newspim.com
  9. topstarnews.net
  10. m.news.nate.com
  11. cbci.co.kr
  12. thebell.co.kr
  13. joongangenews.com
  14. investing.com
  15. kr.investing.com

Report written 2026-11-11 · Data as of 2026-11-10

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis